Neuralstem announces publication of phase 1 trial results of NSI-566
Category: #health  By Pankaj Singh  Date: 2019-07-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Neuralstem announces publication of phase 1 trial results of NSI-566

Subjects were provided immunosuppressive drugs for 28 days after transplantation and were observed for up to 24 months following surgery.

The biopharmaceutical company Neuralstem, Inc. has reportedly announced that it has published a manuscript in Stem Cells Translational Medicine. Apparently, it describes the outcomes of an open label phase 1 clinical study assessing the safety and feasibility of transplantation of its key stem cell asset, NSI-566, for the treatment motor deficits that occur due to ischemic stroke. 

Sources claim that the manuscript summarizes the outcomes of an open label study which was executed at BaYi Brain Hospital, Beijing, China, with Professor Xu Ruxiang. All the nine subjects in the trial had endured chronic motor deficits due to an ischemic stroke 5-24 months before the enrollment. The patients were parted into three groups taking intracerebral injections of NSI-566 cells summing up to 12, 24, or 72 million cells.

Apparently, subjects were provided immunosuppressive drugs for 28 days after transplantation and were observed for up to 24 months following surgery. The therapy was well endured at all dosages and patients showed stable growths in Fugl-Meyer Motor Scores from starting point. This apparently indicates that the procedure is safe and may have potential to offer benefit to patients enduring motor deficits from stroke.

Dr. Ken Carter, Executive Chairman, Neuralstem, reportedly stated that the company has been grateful to the partners at BaYi Brain Hospital and to the subjects who participated in the trial. Although it was a small feasibility trial, the company has been encouraged by the safety profile of the procedure, which has led it to initiate a placebo-controlled study at the same site in September 2018.

For the record, ischemic stroke is the most common type of stroke which occurs due to a hindrance within a blood vessel delivering blood to the brain. Around 15 million individuals globally suffer stroke, out of which nearly 87 percent are ischemic strokes. Post-stroke motor shortfalls include paralysis in legs and arms and can be permanent.

Source credit: https://www.neuralstem.com/news-media/press-releases/detail/264/neuralstem-announces-publication-of-results-from-phase-1



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...